🧾 What This Document Is

This is a Form 6-K, a report that foreign companies listed on U.S. stock exchanges must file with the SEC. Think of it as a "here's what's new" update for investors. This specific filing from April 2026 is all about a significant management change at the company.

👉 In simple terms: It's an official announcement telling shareholders that the company's President is retiring and new leaders are stepping into key roles.

🏢 What The Company Does

Adlai Nortye Ltd. (ANL) is a biopharmaceutical company. While this filing doesn't detail their specific drugs, the leadership backgrounds strongly suggest they are focused on research, development, and commercialization of new medicines, likely in the oncology (cancer) space given the professionals' histories.

👉 In simple terms: They are a drug development company trying to bring new treatments to patients, and they're updating us on who's leading the charge.

👥 The Leadership Shuffle

This is the core of the filing. Three key personnel changes took effect on April 1, 2026:

🚀 New President: Archie Tse, M.D., Ph.D.

• What: Promoted from Head of R&D to President, while keeping his R&D role.
• Why it matters: This consolidates strategic leadership and R&D oversight under one person. Dr. Tse brings deep big-pharma experience from companies like MSD and Daiichi-Sankyo, and a strong scientific background with dual doctorates from USC. This signals a continued focus on science-driven growth.

🚀 New CFO: Dr. Ye

• What: Promoted from interim CFO and VP of Business Development to permanent Chief Financial Officer, while retaining his commercial strategy role.
• Why it matters: Making the CFO permanent adds stability. Dr. Ye's blend of financial oversight, business development, and commercial strategy experience (from companies like Syneos Health and GenScript) is crucial for a biotech firm that needs to fund research and eventually sell its drugs.

➡️ Retiring President: Dr. Kaiyang Tang

• What: Stepped down as President but will stay on as a "Corporate Strategy Professor" to advise the company.
• Why it matters: This is an orderly transition, not a sudden exit. The company states there are no disputes and operations are unaffected. Retaining him in an advisory role helps ensure continuity of knowledge and strategy.

⚖️ Big Picture: What This Signals

👍 Strengths & Positives:

• Smooth Transition: The retiring President is staying on as an advisor, and the company explicitly says there's no operational disruption.
• Strong Scientific & Commercial Leadership: The new President and CFO both have impressive scientific credentials (MDs/PhDs) combined with significant industry experience in both development and commercialization—a powerful combination for a biopharma company.
• No Red Flags: The filing notes neither new appointee has any concerning conflicts of interest or family ties to the board, which is good governance.

⚠️ Risks & Considerations:

• Execution Risk: Any leadership change, especially combining top roles (President + Head of R&D), creates a period where new dynamics must be established. The success of this new structure is now a key focus.
• Continuity of Vision: While Dr. Tang remains as an advisor, the primary strategic driver shifts to Dr. Tse. Investors will watch to see if the company's direction evolves under the new leadership.

🧠 The Analogy

Imagine a rocket ship (the company) that's in the middle of a critical mission to reach a new planet (developing a drug). This filing announces that the Mission Commander (President Dr. Tang) is moving to a special consultant role, while the Chief Scientist (Dr. Tse) is taking over as Commander, and the Business & Fuel Manager (Dr. Ye) is now the permanent CFO. The crew is changing, but the mission continues, and the new leaders are both highly qualified veterans of similar voyages.

📇 Key Contacts & People

• Archie Tse, M.D., Ph.D. - Appointed President & Head of Research and Development (effective April 1, 2026)
• Dr. Ye - Appointed Chief Financial Officer (effective April 1, 2026)
• Dr. Kaiyang Tang - Retired as President, now Corporate Strategy Professor to the Company

(Note: The filing does not provide direct email or phone contact information for these individuals.)

🧩 Final Takeaway

Adlai Nortye Ltd. executed a planned executive transition, elevating two internal, highly-qualified scientific and business leaders to the top roles of President and CFO. The move consolidates R&D and commercial strategy leadership and appears orderly, aiming to maintain momentum in the company's drug development mission without disruption.